T14 TJ DaRenTang USD
- 2.000
- 0.0000.00%
TJ DaRenTang USD News
Tianjin Pharmaceutical's Q1 Attributable Profit Slips 3%
Tianjin Pharmaceutical (SGX:T14) posted an attributable profit of 387.3 million yuan in the first quarter, down 3% from 400.8 million yuan a year earlier. Earnings per share in the three months ended
Express News | Da Ren Tang: Net profit from mother for the first quarter was 387 million yuan, down 3.36% year on year
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Tianfeng Securities released a research report on April 19 stating that Daren Tang (600329.SH) was rated to increase its holdings. The main reasons for the rating include: 1) the “three core and nine wings” strategy is progressing steadily, with significa
Tianfeng Securities released a research report on April 19 stating that Daren Tang (600329.SH) was rated to increase its holdings. The main reasons for the rating include: 1) the “three core and nine wings” strategy is progressing steadily, with significant growth in core products; 2) steady improvement in profitability; and 3) impressive growth in overseas markets. (Mainichi Keizai Shimbun)
A-share changes | Daren Tang rose 8% in the afternoon, and industrial revenue reached a new high last year
Glonghui, April 1 | Daren Tang (600329.SH) increased its increase to 8% in the afternoon, and the stock price returned to the 30 yuan mark, with a total market value of 23.08 billion yuan. The company announced after the market on Friday that net profit for 2023 was 987 million yuan, an increase of 14.49% over the previous year, and plans to distribute 10 12.8 yuan. Among them, the company's industrial revenue was 4.930 billion yuan, maintaining double-digit year-on-year growth and reaching a new high. According to Fangzheng Securities reviews, the company has achieved remarkable results in deepening its core products, and its performance has exceeded expectations. Maintain a “Recommended” rating.
Daren Tang (600329.SH) announced its 2023 annual results, with net profit of 987 million yuan, an increase of 14.49% over the previous year. It plans to distribute 10 to 12.8 yuan
According to the Zhitong Finance App, Daren Tang (600329.SH) disclosed the 2023 annual report. The company achieved revenue of 8.222 billion yuan in 2023, a year-on-year decrease of 0.33%; net profit to mother of 987 million yuan, an increase of 14.49%; deducted non-net profit of 952 million yuan, an increase of 23.8%; and basic earnings per share of 1.28 yuan. The company plans to distribute a cash dividend of 12.8 yuan (tax included) for every 10 shares to all shareholders. In 2023, the company will firmly implement “focus on the market, effective innovation, organizational governance, co-creation and sharing, drive both industry and finance, control capital and loss, digital empowerment, and cultural goods
Singapore Index Slips Into Red on Weak US Data; OCBC Shares Close Flat Following Pricing of Perpetual Capital Securities
Singapore's Straits Times Index erased yesterday's gains to close in the negative territory on Wednesday, tracking overnight losses on Wall Street after newly released US trade data showed a weakening
Daren Tang fell to a standstill. Industry insiders revealed that it may be related to the mixed reform of the majority shareholders
Gelonghui, January 10 | According to brokerage China, Daren Tang suddenly fell to a standstill today. According to Daren Tang's announcement, the incident may be due to the fact that 70 million shares of the company's shares held by Tianjin Pharmaceutical Group Co., Ltd., the controlling shareholder of the company were frozen, and the applicant for the freeze was the Shanghai Supervisory Commission. The reason for the application was to handle the case. “A situation where the supervisory authority of one place freezes state-owned assets in another place.” Very rare. So what exactly is the reason? Industry insiders revealed that this may be related to the mixed reform of Tianjin Pharmaceutical Group, the majority shareholder of Daren Tang. At the end of 2020, Tianjin Jinlian Investment Holdings Co., Ltd. and Shanghai Industrial Group Co., Ltd. held a mixed reform agreement with Tianjin Pharmaceutical Group
Portion of Tianjin Pharmaceutical Controlling Shareholder's Shares Placed Under Judicial Freeze
A portion of Tianjin Pharmaceutical (SGX:T14) controlling shareholder Tianjin Pharmaceutical Holdings' shares have been placed under judicial freeze, according to a Tuesday bourse filing. The shares,
Tianjin Pharmaceutical Taps Affiliate for Brand Promotion
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) will engage Tianjin Pharmaceutical Group Marketing for brand promotion and marketing business expansion. Under the agreement, Tianjin Pharmaceutical
Tianjin Pharmaceutical Hires Contractor for Renovation of Workshop, Warehouses
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) entered into a construction contract with Tianjin Pharmaceutical Design Institute for the decoration of a workshop and renovation of warehouses. Unde
Da Ren Tang (600329.SH): Intends to sign a contract with Tianjin Pharmaceutical Design Institute Co., Ltd.
Gelonghui (600329.SH) announced on December 19丨Da Rentang () announced that in order to integrate the medicinal herbs and tablet business lines and achieve integrated management of tablets and related businesses, the company plans to build a new tablet production workshop, decoction center and supporting facilities in the existing Qingguang South Reservoir area, and upgrade warehouses in the northern storage area. Based on this plan, the company plans to carry out the “Jinyao Da Rentang Drink Factory Relocation and Renovation Project - Frying Workshop Single Project” and the “Jinyao Da Rentang Pharmaceutical Company Qingguang Reservoir North Reservoir Area Renovation Project - 27 #29 #43 #库改造工程” project. According to the bidding results, Tianjin Pharmaceutical Design Institute Co., Ltd.
Da Ren Tang (600329.SH): Some products note the lifting of restrictions and adjustments and changes in the “National Health Insurance Catalogue”
<国家基本医疗保险、工伤保险和生育保险药品目录（2023年）>Gelonghui, December 15|Da Rentang (600329.SH) announced that the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Notice on Issuance”. In the “2023 Medical Insurance Catalogue”, the comment restrictions on some products of Jinyao Da Rentang Group Co., Ltd. have been lifted or adjusted. The content of the comment restrictions on the company's related products has been partially adjusted, and some restrictions have been lifted, which is expected to have a positive effect on the future promotion and application of the company's related products. More patients will benefit from the adjustment of health insurance restrictions
Da Ren Tang (600329.SH): The shareholding structure of the controlling shareholder has changed
Gelonghui (600329.SH) announced on November 22|Da Rentang () announced that it recently received the “Notice Letter on Changes in the Shareholding Structure of Pharmaceutical Group” from the controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., which adjusted the original pharmaceutical group equity transfer plan according to the overall deployment and strategic planning arrangements of the superior units of the pharmaceutical group's shareholders. The equity structure of the Pharmaceutical Group has changed, and the registration of industrial and commercial changes in equity matters has been completed. Tianjin Bohai Guoxin Technology Co., Ltd., a shareholder of Pharmaceutical Group, used its 33% stake in Pharmaceutical Group to increase capital to its wholly-owned subsidiary Tianjin Guoyu Enterprise Management Co., Ltd.
Traditional Chinese medicine concept stocks are once again active, and Ta Ren Tang rises and stops
Gelonghui November 20 | ST Jiyao rose more than 10%, Da Rentang rose and stopped, Taiji Group rose more than 5%, and Jiaying Pharmaceutical, Jianmin Group, Guangdong Wannianqing, and Connbay followed suit. According to the news, Wang Zhiyong, deputy director of the State Administration of Traditional Chinese Medicine, recently stated at the 2023 China Pharmaceutical Industry Development Conference that the next step is to further strengthen policy supply, increase protection, maintain the safety of traditional Chinese medicine development, effectively transform the resource advantages of traditional Chinese medicine into industrial advantages and competitive advantages, and add glory to the high-quality development of the pharmaceutical industry through the iterative opening of the traditional Chinese medicine industry.
Chinese pharmaceutical stocks rose, Da Rentang rose more than 7%
Gelonghui November 20 | Da Rentang rose more than 7%, Jiaying Pharmaceutical and Taiji Group rose more than 3%, and Tailong Pharmaceutical, Jianmin Group, and Sunflower Pharmaceutical followed suit.
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a good company can see its share price rise well over 100%. For example, the Tianji
Private Companies Own 43% of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Shares but Retail Investors Control 46% of the Company
Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Da Ren Tang (600329.SH): Drugs such as Da Ren Tang Qingfeng Detox Tablets and Pediatric Fitness Tablets can be selected
Gelonghui November 2 | Da Rentang (600329.SH) said on the investor interactive platform that mycoplasma and viral infections are mainly determined by the environment and autoimmunity. Avoiding high-risk environments is a prerequisite, and improving the body's immunity is also critical. Medications such as Daren Tang Qingfeng antidote tablets and pediatric fitness tablets can be used as options.
Analysis
Price Target
No Data
